News Snapshot:
Nov. 17 (UPI) -- A vaccine against COVID-19 developed in China safely produces antibodies against the virus in 92% of the people who receive it, according to a study published Tuesday by The Lancet Infectious Diseases . Still, antibody levels among participants receiving the shot, called CoronaVac, were lower than those seen in patients who have recovered following infection, the researchers said. Advertisement The trial was not designed to assess the effectiveness of the vaccine, however, and those studies are ongoing, they said. "Our findings show that CoronaVac is capable of inducing a quick antibody response within four weeks of...
